Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Greg Spendjian who wrote (10480)	8/8/2002 11:28:53 AM
From: Cal Gary	Read Replies (2) \| Respond to of 14101

Greg, it probably doesn't mean much. Financials are a look at what has happened. Instead a management discussion would deal with outlook, guidance and such. From the previous quarterly. Dioptic sales has been miserable for Q1-Q3. Then the surge in Q4. <g> A product from Varennes might explain the slight increase in Dioptic sales: Revenue for the third quarter of fiscal 2002 was $51,000 compared with $240,000 in the same period last year, a decrease of $189,000 due entirely to lack of ophthalmic product to meet demand. This was precipitated by changes in government regulations, which require each of our products to be revalidated. This process is on-going with our contract manufacturers and we expect a limited number of products to be available during the next quarter. In February, our plant in Varennes began production of validation batches of Diofluor diagnostic strips, the first ophthalmic product to be produced at that facility. This product will be available for sale in the fourth quarter.